The new Code of Practice of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) will take effect Jan. 1, 2019. It replaces the version of the code instituted on Jan. 26, 2012. Member associations of IFPMA (see: link) must incorporate this code into existing national codes no later than Jan. 1, 2019, subject to the guidance set out in Articles (iv) and (v) of the code. To read the new version of the code, go here.
IFPMA mentioned that – with the new code – it is setting the bar higher. It is referring to the high ethical standards it set for itself, compared to other industries, because “our industry is unlike any other – our products can prolong and save lives.”
The two most important changes related to the new code are:
- Several provisions have been updated, including the most important one, which is the provision introducing a ban on gifts and promotional aids.
Other than that, the Complaint Procedure has been updated (for example, an oral hearing in the context of the Appeal Procedure is now possible). In addition, there are some minor changes clarifying issues, such as the rules on events that involve foreign travel. For example, a company can only organize or sponsor events involving travel if a significant proportion of the invited HCPs are from outside the company’s home country, and it makes greater logistical or security sense to hold the event in another country. Another example is exceptional circumstances where the relevant resource or expertise that is the object or subject matter of the event is located outside the company’s home country.
- IFMPA developed the IFPMA Ethos. In this respect they mention: “This change aims to shift from a rules-based to a values-based code.” The Ethos consists of four principles:
The IFMPA Ethos can be found: here.